---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-138737"
form_type: "8-K"
ticker: "CABA"
cik: "0001759138"
company_name: "Cabaletta Bio, Inc."
filed_at: "2025-06-11T23:59:59+00:00"
generated_at: "2026-05-19T13:34:42.399914+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Cabaletta Bio reports strong rese-cel efficacy data in myositis, SLE, and scleroderma at EULAR 2025

## Summary
- 7 of 8 myositis patients achieved clinical response off all immunomodulators; all 4 ASyS/DM patients achieved meaningful TIS response.
- All 7 SLE patients achieved clinical response off immunomodulators and glucocorticoids; all non-renal SLE patients achieved DORIS.
- Both scleroderma patients showed meaningful mRSS improvements after discontinuing all immunomodulators and steroids, sustained to 6 months.
- In 18 patients with ≥4 weeks follow-up, 94% had no or Grade 1 CRS; 89% had no ICANS; enrollment accelerated to 51 patients actively enrolled.
- Company terminated ATM program with TD Cowen; prior sales of ~2.6M shares for $7.9M gross proceeds; $192M unused capacity cancelled.

## SEC filing metadata
- accession: 0001193125-25-138737
- form_type: 8-K
- ticker: CABA
- cik: 0001759138
- company_name: Cabaletta Bio, Inc.
- filed_at: 2025-06-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759138/000119312525138737/0001193125-25-138737-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759138/000119312525138737/d78097d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-138737
- JSON: https://secwatch.observer/filing/0001193125-25-138737.json
- Plain text: https://secwatch.observer/filing/0001193125-25-138737.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.